Brimonidine Tartrate for the Treatment of Injection Related Erythema (BRITE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02568111 |
|
Recruitment Status :
Withdrawn
First Posted : October 5, 2015
Last Update Posted : April 25, 2016
|
Sponsor:
Biogen
Information provided by (Responsible Party):
Biogen
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The primary objective of this study is to evaluate the Injection Related Erythema (IRE) mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel (placebo).
The secondary study objectives are to evaluate the IRE mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel on a more stringent definition scale, in accordance with the primary endpoint of the original brimonidine pivotal trials and participants' satisfaction with the overall appearance of their skin.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Relapsing-Remitting Multiple Sclerosis (RRMS) | Drug: peginterferon beta-1a Drug: brimonidine tartrate Drug: Vehicle Gel | Phase 4 |
Participants naïve to treatment with subcutaneous (SC) interferons or oral Disease Modifying Therapy (DMT) who are about to start PLEGRIDY PEN therapy will be screened for participation in this Phase IV trial. Participants will remain on Plegridy therapy as prescribed by their physician. Plegridy will not be provided to participants by Biogen as a part of this study.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 0 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Supportive Care |
| Official Title: | Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated With Sub-cutaneous Administration of Peginterferon Beta-1a (BRITE) |
| Study Start Date : | February 2016 |
| Estimated Primary Completion Date : | August 2016 |
| Estimated Study Completion Date : | August 2016 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Multiple sclerosis
| Arm | Intervention/treatment |
|---|---|
|
Experimental: brimonidine tartrate
Participants will apply gel to injection site erythema area after IRE development post peginterferon beta-1a injection
|
Drug: peginterferon beta-1a
SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
Other Names:
Drug: brimonidine tartrate Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.
Other Name: Mirvaso |
|
Placebo Comparator: Vehicle Gel
Participants will apply vehicle gel placebo to injection site erythema area after IRE development post peginterferon beta-1a injection
|
Drug: peginterferon beta-1a
SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
Other Names:
Drug: Vehicle Gel Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma. |
Primary Outcome Measures :
- Change in either Clinician's Erythema Assessment (CEA) or Patient Erythema Self-Assessment (PSA) scale measured as at least 1-grade improvement on CEA and/or at least 1-grade improvement on PSA scale assessed by the physician and participant [ Time Frame: Before and after 6 hours of gel application ]Investigator will evaluate participant's erythema (redness) at the site of injection on a scale of 0 (clear) to 4 (severe) with higher scores indicating higher levels of erythema. Participants rate erythema at the site of injection on a scale of 0 (clear) to 4 (severe) with higher scores indicating higher levels of erythema.
Secondary Outcome Measures :
- Composite change in both CEA and PSA scale measured as at least 1-grade improvement on CEA and 1-grade improvement on PSA respectively [ Time Frame: Before and after 6 hours of gel application ]This composite endpoint is considered to be sensitive enough and directly correlated with participants' satisfaction therapy outcomes.
- Composite change in both CEA and PSA scale measured as at least 2-grade improvement on CEA and 2-grade improvement on PSA [ Time Frame: Before and after 6 hours of gel application ]
- Participant's self-assessment of satisfaction with the overall appearance of their skin by using a Patient's Assessment of Appearance (PAA) grading scale [ Time Frame: Before and after 6 hours of gel application ]PAA satisfaction score will describe how satisfied the participants are with the overall appearance of skin on a scale of 0 (very satisfied) to 4 (very dissatisfied).
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- RRMS patients naïve to treatment with SC interferon or oral and/or IV DMT for which PLEGRIDY is deemed necessary by the treating physician.
- Patient willing and able to complete PSA and PAA questionnaires with minimal assistance.
Key Exclusion Criteria:
- Known allergy to any interferon or any component of peginterferon beta-1a.
- Patients with hypersensitivity to Brimonidine topical gel.
- Patients with other skin disorders.
- History of previous treatment with Brimonidine tartrate.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02568111
Sponsors and Collaborators
Biogen
Investigators
| Study Director: | Medical Director | Biogen |
| Responsible Party: | Biogen |
| ClinicalTrials.gov Identifier: | NCT02568111 History of Changes |
| Other Study ID Numbers: |
NLD-PEG-14-10784 2015-002159-89 ( EudraCT Number ) |
| First Posted: | October 5, 2015 Key Record Dates |
| Last Update Posted: | April 25, 2016 |
| Last Verified: | April 2016 |
Keywords provided by Biogen:
|
erythema PLEGRIDY injection site reaction (ISR) MS RRMS |
Additional relevant MeSH terms:
|
Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting Erythema Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases Skin Diseases Skin Manifestations Signs and Symptoms Interferon-beta Interferon beta-1a |
Brimonidine Tartrate Antineoplastic Agents Antiviral Agents Anti-Infective Agents Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Immunologic Factors Adjuvants, Immunologic |